|Bid||1,505.00 x 175400|
|Ask||1,520.00 x 417900|
|Day's range||1,502.50 - 1,512.50|
|52-week range||1,446.50 - 1,745.56|
|PE ratio (TTM)||44.16|
|Earnings date||25 Oct 2017|
|Dividend & yield||1.01 (5.25%)|
|1y target est||1,743.04|
Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ...
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low. The company had already cut its full-year guidance in May to the range of $2 billion-$2.1 billion at constant currency from $2.2 billion. "Price erosion by the entire generics industry has been significant," Brian Hoffmann, president of the company's U.S. generics business told Reuters.
Could ongoing approval issues at Hikma Pharmaceuticals plc (LON: HIK) and rivals help GlaxoSmithKline plc (LON:GSK) preserve its dividend?